Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
CHICAGO (Reuters) - More than half of healthy women who have an annual mammogram will get at least one false positive result over a 10-year period, and 7 to 9 percent will undergo a biopsy that doesn't turn out to show cancer, according to U.S. researchers.
NEW YORK (Reuters Health) - Breast cancer patients who take antioxidants may have an increased or decreased risk of death or recurrent cancer, depending on which vitamin they use, a new study suggests.
NEW YORK (Reuters Health) - Older women taking the breast cancer drug tamoxifen may have an increased risk of developing diabetes, a new study suggests.
NEW YORK (Reuters Health) - Starting breast cancer screening as early as age 25 may help women who carry a genetic mutation linked to a higher risk of cancer live longer, suggests a new study.
(Reuters) - Health insurer Blue Shield of California has decided not to pay for Roche Holding's drug Avastin to treat breast cancer after health advisers said it was not safe or clinically beneficial.
STOCKHOLM (Reuters) - Combining two drugs from Novartis and Pfizer to treat post-menopausal women with a certain type of advanced breast cancer more than doubled the time they lived without their disease getting worse, study data showed on Monday.
STOCKHOLM (Reuters) - Giving breast cancer patients radiotherapy and chemotherapy at the same time significantly cuts the risk their tumors will come back and should be considered as a new treatment approach across the world, cancer experts said on Sunday.
NEW YORK (Reuters Health) - Old, poor and Hispanic women are all more likely to have lymph nodes under the armpit removed unnecessarily during breast cancer surgery, a new study finds.
NEW YORK (Reuters Health) - Women with diets rich in vegetables, fruit and legumes may have a somewhat decreased risk of developing one type of breast cancer, a new study suggests.
The first head-to-head comparison of two aromatase inhibitors showed the treatments had similar outcomes in overall survival and recurrence prevention but one had less impact than the other on bone and heart health.